Related Experiment Videos
ONO-2506. Ono.
1Psychiatry Department, MCN AA-2213, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. Tomas.dePaulis@vanderbilt.edu
Current Opinion in Investigational Drugs (London, England : 2000)
|November 19, 2003
Summary
ONO-2506, a valproic acid homolog, is being investigated for neurological disorders. Clinical trials are evaluating its potential for treating stroke, Alzheimer
Area of Science:
- Neuroscience
- Pharmacology
- Drug Development
Background:
- ONO-2506 is a novel enantiomeric homolog of valproic acid.
- It is being developed by ONO Pharmaceutical for neurological conditions.
Purpose of the Study:
- To evaluate the safety and efficacy of ONO-2506 in treating neurological disorders.
- To assess ONO-2506 for potential therapeutic applications in stroke, Alzheimer's disease, and Parkinson's disease.
Main Methods:
- Phase II clinical trials for acute-phase cerebral infarction (stroke) in the US and Japan using injectable Proglia.
- Phase I clinical trials in the UK for Alzheimer's disease (AD) and Parkinson's disease (PD) using oral Cereact.
- Phase I and II trials for AD, PD, and amyotrophic lateral sclerosis (ALS) in Japan and Europe.
Main Results:
- Ongoing clinical trials indicate progression through Phase I and II stages for various neurological conditions.
- Specific efficacy and safety data from trials are not detailed in the abstract.
Conclusions:
- ONO-2506 demonstrates potential as a therapeutic agent for cerebrovascular and neurodegenerative diseases.
- Further clinical evaluation is necessary to establish its therapeutic value and safety profile.